Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P16 vs EU-approved Avastin in first-line treatment of metastatic or recurrent non-squamous non-small cell lung cancer
2018-002147-28Phase 3Completed
- Sponsor
- Celltrion
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Celltrion. Primary endpoint: Objective response rate during Induction Study Period. Started Aug 2018; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-002147-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002147-28.